Innospec Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Shareholders of Innospec Inc. (NASDAQ:IOSP) will be pleased this week, given that the stock price is up 11% to US$120 following its latest third-quarter results. Innospec reported US$443m in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of US$1.33 beat expectations, being 6.4% higher than what the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Innospec after the latest results.

Check out our latest analysis for Innospec

Taking into account the latest results, the most recent consensus for Innospec from three analysts is for revenues of US$1.94b in 2025. If met, it would imply a satisfactory 3.6% increase on its revenue over the past 12 months. Per-share earnings are expected to ascend 15% to US$6.63. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$1.94b and earnings per share (EPS) of US$7.07 in 2025. The analysts seem to have become a little more negative on the business after the latest results, given the small dip in their earnings per share numbers for next year.

The average price target fell 6.5% to US$129, with reduced earnings forecasts clearly tied to a lower valuation estimate. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Innospec analyst has a price target of US$135 per share, while the most pessimistic values it at US$122. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Innospec is an easy business to forecast or the the analysts are all using similar assumptions.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's pretty clear that there is an expectation that Innospec's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 2.9% growth on an annualised basis. This is compared to a historical growth rate of 9.3% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 4.6% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Innospec.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Innospec. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Innospec's revenue is expected to perform worse than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Innospec going out to 2026, and you can see them free on our platform here.

However, before you get too enthused, we've discovered 1 warning sign for Innospec that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.